Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOPE ATRT01 international trial for children with atypical teratoid/rhabdoid tumors
NL-OMON58829Phase 3Recruiting
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of doxorubicin in Atypical teratoid rhabdoid tumor (ATRT) (4 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall survival. Started Sep 2022; status: recruiting.
02
Drugs
doxorubicin
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NL-OMON58829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58829.